A decline in the leukaemic blast cell numbers together with decreasing PLA2R1 promoter methylation during ongoing ALL treatment suggest that the overall increase of PLA2R1 methylation in BM and PB samples at diagnosis is caused by leukaemic blast cells. The gene discussed is PLA2R1; the disease is acute lymphoblastic leukemia.